Liquid Biopsy of Head and Neck Cancer Patients in Blood and Saliva

NCT ID: NCT05122507

Last Updated: 2023-04-12

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 200 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2017-05-08
• Study Completion Date: 2023-04-30

Brief Summary

Prospective study for therapy monitoring of locally advanced and metastatic head and neck cancer patients by detection of circulating tumor nucleic acids in peripheral blood and saliva

Detailed Description

Clinical examination including imaging and - if necessary - tissue biopsy sampling - is the current clinical standard in therapy monitoring of metastatic head and neck tumors. This includes both the initial diagnosis, the assessment of the therapeutic response during ongoing chemotherapy / radiochemotherapy and follow-up care with the aim of detecting recurrences at an early stage. The detection of circulating nucleic acids as well as proteins in the peripheral blood and saliva could represent a minimally invasive and exact method for the assessment of the tumor burden, for the early detection of recurrences and for the individual assessment of the therapy response in patients with head and neck cancer. The present study aims to evaluate the value of tumor-specific nucleic acids and proteins in peripheral blood and saliva as possible biomarkers for minimally invasive therapy monitoring of head and neck tumors. For this purpose, Next Generation Sequencing (NGS), ELISA and quantitative polymerase chain reaction (PCR) methods are used as diagnostic methods. NGS initially enables the creation of a genetic profile of the primary tumor with targeted massive parallel sequencing of frequently mutated genes in head and neck tumors. The amount of nucleic acids in the peripheral blood and saliva is then quantified by means of digital PCR with the aid of specifically designed digital PCR assays. In addition, tumor-associated nucleic acids and proteins in the primary tumor, blood and saliva are examined. The aim is to examine if the amount of tumor specific circulating nucleic acids and the concentration of protein biomarkers found in the blood and saliva are associated with the response to treatment, early detection of recurrence, and the overall prognosis.

Conditions

Head and Neck Squamous Cell Carcinoma

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Eligibility Criteria

Inclusion Criteria

• Head and neck squamous cell carcinoma (HNSCC)
• Written informed consent

Exclusion Criteria

• Neoplasms other than HNSCC

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Technical University of Munich

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Irina Kerle, MD

Role: PRINCIPAL_INVESTIGATOR

Technical University of Munich

Markus Wirth, MD

Role: PRINCIPAL_INVESTIGATOR

Technical University of Munich

Christof Winter, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Technical University of Munich

Locations

Klinikum rechts der Isar der Technischen Universität München

Munich, , Germany

Site Status: RECRUITING

Countries

Germany

Central Contacts

Markus Wirth, MD

Role: CONTACT

markus.wirth@tum.de

+49 89 4140 ext. 9416

Christof Winter, MD, PhD

Role: CONTACT

christof.winter@tum.de

+49 89 4140 ext. 4765

Facility Contacts

Markus Wirth, MD

Role: primary

markus.wirth@tum.de

+49 89 4140 ext. 9416

Other Identifiers

KOHACIN

Identifier Type: -

Identifier Source: org_study_id